Compare Mesoblast Limited (MESO) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Boston Beer Company Inc — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while Boston Beer Company Inc trades at $176.05 (market cap $1.88B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| MESO | SAM | |
|---|---|---|
Market Cap | $2.17B | $1.88B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $260.05 |
52-Week Low | $12.88 | $161.08 |
Enterprise Value | $2.17B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Boston Beer Company (SAM) trades at $180.59, up 1.0% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin and ROE. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst consensus is mixed with 74% hold ratings and a $204.33 price target, suggesting modest upside potential from current levels.
SAM faces near-term challenges including volume declines and competitive pressures in the hard seltzer segment, offset by strong cash flow generation and innovation in Beyond Beer categories. The company's improved gross margins and cost-saving initiatives provide some stability, but investor sentiment remains cautious ahead of Q2 earnings. The stock presents a balanced risk-reward profile with potential upside to analyst targets but requires monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
